| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunohistochemistry - paraffin section; human; 1:100; fig 2a
| Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell. 2018;172:373-386.e10 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; fig 1c
| Dobosz M, Haupt U, Scheuer W. Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application schedule. MAbs. 2017;9:140-153 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:200; tbl 5
| Liu Y, Wang K, Xing H, Zhai X, Wang L, Wang W. Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers. Oncol Lett. 2016;12:1240-1256 pubmed |
- immunohistochemistry - paraffin section; human; 1:100; loading ...; tbl 1
| Chung M, Lee J, Kim S, Suh Y, Choi H. Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer. Medicine (Baltimore). 2016;95:e3689 pubmed publisher |
- immunohistochemistry; human; 1:200; loading ...
| Matsumoto H, Thike A, Li H, Yeong J, Koo S, Dent R, et al. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. Breast Cancer Res Treat. 2016;156:237-47 pubmed publisher |
- immunohistochemistry; human; ready to use
| KapucuoÄŸlu N, Bozkurt K, BaÅŸpınar Å, Koçer M, EroÄŸlu H, Akdeniz R, et al. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Pathol Res Pract. 2015;211:740-7 pubmed publisher |
- immunohistochemistry - paraffin section; human; loading ...; fig 1f
| Wang D, Pang Z, Clarke G, Nofech Mozes S, Liu K, Cheung A, et al. Ki-67 Membranous Staining: Biologically Relevant or an Artifact of Multiplexed Immunofluorescent Staining. Appl Immunohistochem Mol Morphol. 2016;24:447-52 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:200
| Koh V, Lim J, Thike A, Cheok P, Thu M, Tan V, et al. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients. Breast Cancer Res Treat. 2015;152:293-304 pubmed publisher |
- immunohistochemistry; human; 1:100
| de Deus Moura R, Carvalho F, Bacchi C. Breast cancer in very young women: Clinicopathological study of 149 patients ≤25 years old. Breast. 2015;24:461-7 pubmed publisher |
- immunohistochemistry - paraffin section; human
| Nwafor C, Keshinro S. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience. Niger J Clin Pract. 2015;18:553-8 pubmed publisher |
- immunohistochemistry - paraffin section; human; tbl 2
| Savci Heijink C, Halfwerk H, Hooijer G, Horlings H, Wesseling J, van de Vijver M. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 2015;150:547-57 pubmed publisher |
- immunohistochemistry; human; 1:200
| Oon M, Thike A, Tan S, Tan P. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast. Breast Cancer Res Treat. 2015;150:31-41 pubmed publisher |
- immunohistochemistry - paraffin section; human
| Tu J, Yu Y, Liu W, Chen S. Significance of human epidermal growth factor receptor 2 expression in colorectal cancer. Exp Ther Med. 2015;9:17-24 pubmed |
- immunohistochemistry; human; 1:100
| Carvalho F, Bacchi L, Pincerato K, van de Rijn M, Bacchi C. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. BMC Womens Health. 2014;14:102 pubmed publisher |
- immunohistochemistry; human
| Dean S, Perks C, Holly J, Bhoo Pathy N, Looi L, Mohammed N, et al. Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer. Am J Clin Pathol. 2014;141:323-33 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:200
| Jackson D, Atkinson J, Guevara C, Zhang C, Kery V, Moon S, et al. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. PLoS ONE. 2014;9:e83865 pubmed publisher |
- immunohistochemistry; human; 1:100
| Clarke G, Zubovits J, Shaikh K, Wang D, Dinn S, Corwin A, et al. A novel, automated technology for multiplex biomarker imaging and application to breast cancer. Histopathology. 2014;64:242-55 pubmed publisher |
- immunohistochemistry; human; 1:50
| Kuijpers C, Moelans C, van Slooten H, Horstman A, Hinrichs J, Al Janabi S, et al. Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification in invasive breast cancer. PLoS ONE. 2013;8:e82018 pubmed publisher |
- immunocytochemistry; human
- western blot; human
| Galletti G, Sung M, Vahdat L, Shah M, Santana S, Altavilla G, et al. Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip. 2014;14:147-56 pubmed publisher |
- immunohistochemistry; human; 1:200
| Gulbahce H, Vanderwerf S, Blair C, Sweeney C. Lobulitis in nonneoplastic breast tissue from breast cancer patients: association with phenotypes that are common in hereditary breast cancer. Hum Pathol. 2014;45:78-84 pubmed publisher |
- immunohistochemistry; human; 1:200
| Gulbahce H, Sweeney C, Surowiecka M, Knapp D, Varghese L, Blair C. Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors. Hum Pathol. 2013;44:2427-31 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; fig 2
| Vlug E, van de Ven R, Vermeulen J, Bult P, van Diest P, Derksen P. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer. Cell Oncol (Dordr). 2013;36:375-84 pubmed publisher |
- immunohistochemistry; human; 1:500
| Nunes C, Rocha R, Buzelin M, Balabram D, de Souza Foureaux F, Porto S, et al. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma. J Clin Pathol. 2013;66:946-50 pubmed publisher |
- immunohistochemistry; human; 1:200
| Do S, Kim K, Kim D, Chae S, Park Y, Park C, et al. Associations between the Expression of Mucins (MUC1, MUC2, MUC5AC, and MUC6) and Clinicopathologic Parameters of Human Breast Ductal Carcinomas. J Breast Cancer. 2013;16:152-8 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; tbl 1
| Aguiar F, Mendes H, Cirqueira C, Bacchi C, Carvalho F. Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ. Clinics (Sao Paulo). 2013;68:638-43 pubmed publisher |
- immunohistochemistry; human
| Zhang X, Claerhout S, Prat A, Dobrolecki L, Petrovic I, Lai Q, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013;73:4885-97 pubmed publisher |
- immunohistochemistry; human
| Postma E, Verkooijen H, van Diest P, Willems S, van den Bosch M, van Hillegersberg R. Discrepancy between routine and expert pathologists' assessment of non-palpable breast cancer and its impact on locoregional and systemic treatment. Eur J Pharmacol. 2013;717:31-5 pubmed publisher |
- immunocytochemistry; human; 1:40
| van Hemel B, Suurmeijer A. Effective application of the methanol-based PreservCyt(™) fixative and the Cellient(™) automated cell block processor to diagnostic cytopathology, immunocytochemistry, and molecular biology. Diagn Cytopathol. 2013;41:734-41 pubmed publisher |
- immunohistochemistry; human; 1:100
| Limaye S, Posner M, Krane J, Fonfria M, Lorch J, Dillon D, et al. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013;18:294-300 pubmed publisher |
- immunohistochemistry; human; 1:100
| D Alfonso T, Liu Y, Chen Z, Chen Y, Cimino Mathews A, Shin S. SP3, a reliable alternative to HercepTest in determining HER-2/neu status in breast cancer patients. J Clin Pathol. 2013;66:409-14 pubmed publisher |
- immunohistochemistry; human; 1:100
| Prins M, Ruurda J, van Diest P, van Hillegersberg R, ten Kate F. The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study. Ann Oncol. 2013;24:1290-7 pubmed publisher |
- immunohistochemistry; human; 1:100
| Vermeulen J, Kornegoor R, van der Wall E, van der Groep P, van Diest P. Differential expression of growth factor receptors and membrane-bound tumor markers for imaging in male and female breast cancer. PLoS ONE. 2013;8:e53353 pubmed publisher |
- immunocytochemistry; human; 1:50
- immunohistochemistry; human
| Jambal P, Badtke M, Harrell J, Borges V, Post M, Sollender G, et al. Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Breast Cancer Res Treat. 2013;137:431-48 pubmed publisher |
- immunohistochemistry; human
| Rau K, Huang C, Chiu T, Chen Y, Lu C, Liu C, et al. Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers. Exp Ther Med. 2012;4:231-236 pubmed |
- immunohistochemistry; human; 1:100
| Kornegoor R, Verschuur Maes A, Buerger H, Hogenes M, de Bruin P, Oudejans J, et al. Immunophenotyping of male breast cancer. Histopathology. 2012;61:1145-55 pubmed publisher |
- immunohistochemistry; human; 1:200
| Iqbal J, Thike A, Cheok P, Tse G, Tan P. Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer. Histopathology. 2012;61:652-9 pubmed publisher |
- immunohistochemistry; human; 1:100
| Vermeulen J, van Brussel A, van der Groep P, Morsink F, Bult P, van der Wall E, et al. Immunophenotyping invasive breast cancer: paving the road for molecular imaging. BMC Cancer. 2012;12:240 pubmed publisher |
- immunohistochemistry; human
| Dekker T, Borg S, Hooijer G, Meijer S, Wesseling J, Boers J, et al. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res. 2012;14:R93 pubmed |
- immunohistochemistry; human; 1:100
| Vermeulen J, van de Ven R, Ercan C, van der Groep P, van der Wall E, Bult P, et al. Nuclear Kaiso expression is associated with high grade and triple-negative invasive breast cancer. PLoS ONE. 2012;7:e37864 pubmed publisher |
- immunohistochemistry; human; 1:100
| Hoefnagel L, Moelans C, Meijer S, van Slooten H, Wesseling P, Wesseling J, et al. Prognostic value of estrogen receptor ? and progesterone receptor conversion in distant breast cancer metastases. Cancer. 2012;118:4929-35 pubmed publisher |
- immunohistochemistry; human; 1:100
| Sanli Y, Kuyumcu S, Ozkan Z, Işık G, Karanlik H, Guzelbey B, et al. Increased FDG uptake in breast cancer is associated with prognostic factors. Ann Nucl Med. 2012;26:345-50 pubmed publisher |
- immunohistochemistry; human; 1:100
| Schillaci R, Guzman P, Cayrol F, Beguelin W, Díaz Flaqué M, Proietti C, et al. Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. BMC Cancer. 2012;12:74 pubmed publisher |
- immunohistochemistry; human; 1:100
| Kornegoor R, Verschuur Maes A, Buerger H, van Diest P. The 3-layered ductal epithelium in gynecomastia. Am J Surg Pathol. 2012;36:762-8 pubmed publisher |
- immunohistochemistry; human; 1:100
| Belt E, Brosens R, Delis van Diemen P, Bril H, Tijssen M, van Essen D, et al. Cell cycle proteins predict recurrence in stage II and III colon cancer. Ann Surg Oncol. 2012;19 Suppl 3:S682-92 pubmed publisher |
- immunohistochemistry; human
| MacFarlane R, Seal M, Speers C, Woods R, Masoudi H, Aparicio S, et al. Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist. 2012;17:172-8 pubmed publisher |
- immunohistochemistry; rat; 1:200
| Einbond L, Soffritti M, Degli Esposti D, Tibaldi E, Lauriola M, Bua L, et al. Chemopreventive potential of black cohosh on breast cancer in Sprague-Dawley rats. Anticancer Res. 2012;32:21-30 pubmed |
- immunohistochemistry; human; 1:400
| Reisenbichler E, Horton D, Rasco M, Andea A, Hameed O. Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section. Am J Clin Pathol. 2012;137:102-10 pubmed publisher |
- immunohistochemistry; human
| Liu W, Zhong S, Chen J, Yu Y. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. J Clin Gastroenterol. 2012;46:e31-7 pubmed publisher |
- immunohistochemistry; human; 1:100
- western blot; human
| Jan C, Yu C, Hung M, Harn H, Nieh S, Lee H, et al. Tid1, CHIP and ErbB2 interactions and their prognostic implications for breast cancer patients. J Pathol. 2011;225:424-37 pubmed publisher |
- immunohistochemistry; human; 1:80
| Martins D, Sousa B, Lopes N, Gomes M, Veronese L, Albergaria A, et al. Molecular phenotypes of matched in situ and invasive components of breast carcinomas. Hum Pathol. 2011;42:1438-46 pubmed publisher |
- immunohistochemistry; human; 1:200
| Allison K, Kandalaft P, Sitlani C, Dintzis S, Gown A. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?. Breast Cancer Res Treat. 2012;131:413-24 pubmed publisher |
- immunohistochemistry; human; 1:100
| Heerma van Voss M, van der Groep P, Bart J, van der Wall E, van Diest P. Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer. Cell Oncol (Dordr). 2011;34:3-10 pubmed publisher |
- immunohistochemistry; human
| Boers J, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology. 2011;58:383-94 pubmed publisher |
- immunohistochemistry; human; 1:200
| Ahmed S, Iqbal J, Thike A, Lim A, Lim T, Tien S, et al. HER2/neu revisited: quality and interpretive issues. J Clin Pathol. 2011;64:120-4 pubmed publisher |
- immunohistochemistry; human; 1:25
| Joosse S, Brandwijk K, Mulder L, Wesseling J, Hannemann J, Nederlof P. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. Genes Chromosomes Cancer. 2011;50:71-81 pubmed publisher |
- immunohistochemistry; human; 1:25
| Holstege H, van Beers E, Velds A, Liu X, Joosse S, Klarenbeek S, et al. Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers. BMC Cancer. 2010;10:455 pubmed publisher |
- immunohistochemistry; human
| Tan Y, Han S, Lu Y, Yip C, Sunpaweravong P, Jeong J, et al. The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature survey. Cancer. 2010;116:5348-57 pubmed publisher |
- immunohistochemistry; human; 1:25
| Joosse S, Brandwijk K, Devilee P, Wesseling J, Hogervorst F, Verhoef S, et al. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH. Breast Cancer Res Treat. 2012;132:379-89 pubmed publisher |
- immunohistochemistry; human
| Lee C, Tannock I. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer. 2010;10:255 pubmed publisher |
| Shi M, Liu D, Duan H, Qian L, Wang L, Niu L, et al. The ?2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells. Breast Cancer Res Treat. 2011;125:351-62 pubmed publisher |
- immunohistochemistry; human; 1:3000
| Bueno de Mesquita J, Nuyten D, Wesseling J, VAN Tinteren H, Linn S, van de Vijver M. The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol. 2010;21:40-7 pubmed publisher |
- immunohistochemistry; human; 1:100
| Boone J, van Hillegersberg R, Offerhaus G, van Diest P, Borel Rinkes I, ten Kate F. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis Esophagus. 2009;22:496-504 pubmed publisher |
- immunohistochemistry; human; 1:100
| Liu S, Chia S, Mehl E, Leung S, Rajput A, Cheang M, et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat. 2010;119:53-61 pubmed publisher |
- immunohistochemistry; human; 1:25
| Joosse S, van Beers E, Tielen I, Horlings H, Peterse J, Hoogerbrugge N, et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat. 2009;116:479-89 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:400; tbl 3
- immunohistochemistry; human; 1:400
| Kim T, Huh J, Lee S, Kang H, Kim G, An H. Down-regulation of claudin-2 in breast carcinomas is associated with advanced disease. Histopathology. 2008;53:48-55 pubmed publisher |
- immunohistochemistry; human
| Tan B, Tan L, Yu K, Tan P, Lee M, Sii L, et al. Clinical validation of a customized multiple signature microarray for breast cancer. Clin Cancer Res. 2008;14:461-9 pubmed publisher |
- immunohistochemistry; human; 1:100
| Crabb S, Bajdik C, Leung S, Speers C, Kennecke H, Huntsman D, et al. Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast Cancer Res. 2008;10:R6 pubmed publisher |
- immunohistochemistry; human; 1:100
| Rajput A, Turbin D, Cheang M, Voduc D, Leung S, Gelmon K, et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat. 2008;107:249-57 pubmed |
- immunohistochemistry; human
| Nadasi E, Anga B, Sandor J, Megyesi J, Kelemen D, Mottolese M, et al. Prognostic factors in Hungarian breast cancer patients. Anticancer Res. 2007;27:279-82 pubmed |
- immunohistochemistry; human; 1:200
| Ho B, Tan H, Lee V, Tan P. Preoperative and intraoperative diagnosis of low-grade adenosquamous carcinoma of the breast: potential diagnostic pitfalls. Histopathology. 2006;49:603-11 pubmed |
- immunohistochemistry; human; 1:80
| Ricardo S, Milanezi F, Carvalho S, Leitão D, Schmitt F. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol. 2007;60:1001-5 pubmed |
| Hutten S, Messal H, Lips E, Sheinman M, Ciwinska M, Braams E, et al. Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts. J Pathol. 2024;263:360-371 pubmed publisher |
| Arnli M, Winther T, Lydersen S, Torp S. Prognostic value of ErbB2/HER2 in human meningiomas. PLoS ONE. 2018;13:e0205846 pubmed publisher |
| Ni J, Ramkissoon S, Xie S, Goel S, Stover D, Guo H, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016;22:723-6 pubmed publisher |
| Cheung S, Boey Y, Koh V, Thike A, Lim J, Iqbal J, et al. Role of epithelial-mesenchymal transition markers in triple-negative breast cancer. Breast Cancer Res Treat. 2015;152:489-98 pubmed publisher |
| Vermeulen J, van der Wall E, Witkamp A, van Diest P. Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: paving the way for molecular imaging. Cell Oncol (Dordr). 2013;36:333-40 pubmed publisher |
| Zheng G, Xiong Y, Yi S, Zhang W, Peng B, Zhang Q, et al. 14-3-3? regulation by p53 mediates a chemotherapy response to 5-fluorouracil in MCF-7 breast cancer cells via Akt inactivation. FEBS Lett. 2012;586:163-8 pubmed publisher |
| Naushad S, Pavani A, Rupasree Y, Divyya S, Deepti S, Digumarti R, et al. Association of aberrations in one-carbon metabolism with molecular phenotype and grade of breast cancer. Mol Carcinog. 2012;51 Suppl 1:E32-41 pubmed publisher |
| Lee D, Kim S, Suh Y, Kim S, Kim H, Shim B. Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy. Jpn J Clin Oncol. 2011;41:854-66 pubmed publisher |
| Barok M, Tanner M, Köninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett. 2011;306:171-9 pubmed publisher |
| Teng Y, Tan W, Thike A, Cheok P, Tse G, Wong N, et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res. 2011;13:R35 pubmed publisher |
| Bong P, Zakaria Z, Muhammad R, Abdullah N, Ibrahim N, Emran N, et al. Expression and mutational analysis of GATA3 in Malaysian breast carcinomas. Malays J Pathol. 2010;32:117-22 pubmed |
| Atahan K, Küpeli H, Gür S, Yiğitbaşı T, Baskin Y, Yigit S, et al. The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer. Int J Med Sci. 2011;8:148-55 pubmed |
| Rhodes A, Sarson J, Assam E, Dean S, Cribb E, Parker A. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas. Am J Clin Pathol. 2010;134:621-32 pubmed publisher |
| Lwin Z, Guo C, Salim A, Yip G, Chew F, Nan J, et al. Clinicopathological significance of calreticulin in breast invasive ductal carcinoma. Mod Pathol. 2010;23:1559-66 pubmed publisher |
| Tan M, Wong C, Tan H, Yang X, Ditlev J, Matsuda D, et al. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer. 2010;10:196 pubmed publisher |
| Munjal K, Ambaye A, Evans M, Mitchell J, Nandedkar S, Cooper K. Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients. Asian Pac J Cancer Prev. 2009;10:773-8 pubmed |
| Lopes N, Sousa B, Vieira D, Milanezi F, Schmitt F. Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles. Histopathology. 2009;55:594-9 pubmed publisher |
| Thike A, Cheok P, Jara Lazaro A, Tan B, Tan P, Tan P. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 2010;23:123-33 pubmed publisher |
| Wang C, Iakovlev V, Wong V, Leung S, Warren K, Iakovleva G, et al. Genomic alterations in primary breast cancers compared with their sentinel and more distal lymph node metastases: an aCGH study. Genes Chromosomes Cancer. 2009;48:1091-101 pubmed publisher |
| Behbod F, Kittrell F, LaMarca H, Edwards D, Kerbawy S, Heestand J, et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res. 2009;11:R66 pubmed publisher |
| Freedman O, Amir E, Hanna W, Kahn H, O Malley F, Dranitsaris G, et al. A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2010;119:155-61 pubmed publisher |
| Sassen A, Diermeier Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, et al. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. Breast Cancer Res. 2009;11:R50 pubmed publisher |
| Nofech Mozes S, Hanna W. Toker cells revisited. Breast J. 2009;15:394-8 pubmed publisher |
| Wang L, Jiang Z, Sui M, Shen J, Xu C, Fan W. The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study. BMC Cancer. 2009;9:226 pubmed publisher |
| Rocha R, Nunes C, Sanches F, Rocha G, Oliveira F, Reis Filho J, et al. Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer. Rev Assoc Med Bras (1992). 2009;55:163-8 pubmed |
| Dufloth R, Alves J, Martins D, Vieira D, Chikota H, Zeferino L, et al. Cytological criteria to predict basal phenotype of breast carcinomas. Diagn Cytopathol. 2009;37:809-14 pubmed publisher |
| Rosa F, Silveira S, Silveira C, Bérgamo N, Neto F, Domingues M, et al. Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma. BMC Cancer. 2009;9:90 pubmed publisher |
| Tezel G, Uner A, Yildiz I, Guler G, Takahashi M. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression. Pathol Res Pract. 2009;205:403-8 pubmed publisher |
| Sun L, Wang D, Zubovits J, Yaffe M, Clarke G. An improved processing method for breast whole-mount serial sections for three-dimensional histopathology imaging. Am J Clin Pathol. 2009;131:383-92 pubmed publisher |
| Hanley K, Siddiqui M, Lawson D, Cohen C, Nassar A. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis. Diagn Cytopathol. 2009;37:251-7 pubmed publisher |
| Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown A, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 2008;26:5697-704 pubmed publisher |
| van Dekken H, Hop W, Tilanus H, Haringsma J, van der Valk H, Wink J, et al. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus. Am J Clin Pathol. 2008;130:745-53 pubmed publisher |
| Jensen M, Schoepfer J, Radimerski T, Massey A, Guy C, Brueggen J, et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res. 2008;10:R33 pubmed publisher |
| Cheang M, Voduc D, Bajdik C, Leung S, McKinney S, Chia S, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-76 pubmed publisher |
| Wong S, Chan J, Lo E, Chan A, Wong M, Chan C, et al. The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry. Arch Pathol Lab Med. 2007;131:1047-55 pubmed |
| Selvarajan S, Sii L, Lee A, Yip G, Bay B, Tan M, et al. Parafibromin expression in breast cancer: a novel marker for prognostication?. J Clin Pathol. 2008;61:64-7 pubmed |
| Short S, Yoder B, Tarr S, Prescott N, Laniauskas S, Coleman K, et al. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study. Breast J. 2007;13:130-9 pubmed |
